RJFSA
JAZZ icon

Raymond James Financial Services Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Raymond James Financial Services Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$492K Sell
4,417
-974
-18% -$107K ﹤0.01% 2629
2024
Q2 		$575K Sell
5,391
-584
-10% -$64.2K ﹤0.01% 2433
2024
Q1 		$720K Sell
5,975
-481
-7% -$58.9K ﹤0.01% 2265
2023
Q4 		$794K Sell
6,456
-229
-3% -$28.6K ﹤0.01% 2120
2023
Q3 		$865K Sell
6,685
-3,544
-35% -$472K ﹤0.01% 1991
2023
Q2 		$1.27M Sell
10,229
-1,038
-9% -$140K ﹤0.01% 1788
2023
Q1 		$1.65M Buy
11,267
+479
+4% +$70.9K ﹤0.01% 1605
2022
Q4 		$1.72M Sell
10,788
-5,379
-33% -$788K ﹤0.01% 1526
2022
Q3 		$2.15M Buy
16,167
+4,845
+43% +$737K ﹤0.01% 1381
2022
Q2 		$1.77M Buy
11,322
+104
+0.9% +$16K ﹤0.01% 1506
2022
Q1 		$1.75M Sell
11,218
-843
-7% -$122K ﹤0.01% 1574
2021
Q4 		$1.54M Sell
12,061
-12,803
-51% -$1.68M ﹤0.01% 1702
2021
Q3 		$3.24M Buy
24,864
+10,325
+71% +$1.56M 0.01% 1208
2021
Q2 		$2.58M Buy
14,539
+12,758
+716% +$2.21M 0.01% 1336
2021
Q1 		$293K Sell
1,781
-3,339
-65% -$549K ﹤0.01% 2641
2020
Q4 		$845K Buy
+5,120
New +$763K ﹤0.01% 1800
2020
Q1 		– Sell
-1,610
Closed -$240K – 2647
2019
Q4 		$240K Sell
1,610
-596
-27% -$81.1K ﹤0.01% 2461
2019
Q3 		$283K Buy
2,206
+267
+14% +$35.8K ﹤0.01% 2285
2019
Q2 		$276K Sell
1,939
-141
-7% -$18.9K ﹤0.01% 2317
2019
Q1 		$297K Sell
2,080
-361
-15% -$47.1K ﹤0.01% 2249
2018
Q4 		$303K Sell
2,441
-8,589
-78% -$1.27M ﹤0.01% 1992
2018
Q3 		$1.85M Buy
11,030
+3,546
+47% +$610K 0.01% 1127
2018
Q2 		$1.29M Sell
7,484
-1,163
-13% -$190K 0.01% 1271
2018
Q1 		$1.31M Buy
8,647
+2,743
+46% +$402K 0.01% 1159
2017
Q4 		$795K Buy
5,904
+3,297
+126% +$457K 0.01% 1437
2017
Q3 		$381K Buy
2,607
+253
+11% +$38.3K ﹤0.01% 1884
2017
Q2 		$366K Sell
2,354
-53
-2% -$8.11K ﹤0.01% 1869
2017
Q1 		$349K Sell
2,407
-298
-11% -$38.8K ﹤0.01% 1806
2016
Q4 		$295K Buy
+2,705
New +$301K ﹤0.01% 1812
2016
Q3 		– Sell
-1,567
Closed -$221K – 2350
2016
Q2 		$221K Buy
+1,567
New +$231K ﹤0.01% 1918

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Raymond James Financial Services Advisors's JAZZ Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 18% in Q3 2024, selling an estimated $107K and leaving 4,417 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #2629.

Raymond James Financial Services Advisors first reported a position in JAZZ in Q2 2016 and has held it in 30 quarters since. The position peaked at $3.24M in Q3 2021. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Raymond James Financial Services Advisors held 4,417 shares of Jazz Pharmaceuticals worth $492K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 974 Jazz Pharmaceuticals shares in Q3 2024, an estimated $107K.
  • Jazz Pharmaceuticals made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2629 holding.
  • Raymond James Financial Services Advisors first reported a position in Jazz Pharmaceuticals in Q2 2016 and has held it in 30 quarters since.
  • Raymond James Financial Services Advisors's Jazz Pharmaceuticals position peaked at $3.24M in Q3 2021.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.